在RSV-A F蛋白中的S190R突变损害了nirsevimab的结合和中和能力
Sapir Cordela1, Jhonatan Harari1, Romila Moirangthem1
1Department of Immunology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron 1 St, Haifa 3525422, Israel.
Virus evolution
|February 9, 2026
概括
呼吸道同胞病毒 (RSV) 的新突变 (S190R) 可以帮助病毒逃避预防性抗体nirsevimab. 这种S190R突变减少了nirsevimab.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 一种单克隆抗体Nirsevimab于2023年被美国FDA批准用于预防婴儿呼吸道同胞病毒 (RSV) 感染.
- 被动免疫疗法在预防病毒感染方面取得了重大进展.
- 最初的研究表明,在突破性感染中,RSV-A F蛋白的nirsevimab结合部位不受影响.
研究的目的:
- 为了研究主要抗体结合部位之外的潜在的耐尼塞维马布基因突变.
- 在暴露于nirsevimab后,分析RSV-A在单个基因组水平上的突变格局.
主要方法:
- 单基因组测序RSV-A以识别突变.
- 评估S190R突变对nirsevimab结合和中和的影响.
- 在细胞系和人类器官中分析S190RRSV-A复制.
主要成果:
- 在大多数病毒中,在nirsevimab暴露后,在RSV-A F蛋白的抗原位点V中确定了一种特定的氨基酸替代物S190R.
- 证明S190R突变通过影响抗体进入位点 Ø 表观点来降低nirsevimab的结合和中和功效.
- 复制研究表明,S190R突变损害了RSV-A.的病毒适应性.
结论:
- 这种S190R突变代表了一种潜在的病毒机制,可以逃避尼尔塞维马布介导的免疫力.
- 了解这些耐药性机制对于开发和维护有效的RSV预防策略至关重要.
更多相关视频
07:45A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
Published on: June 27, 2011
13.0K
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
43.4K
相关概念视频
Mutations
94.6K
Overview
94.6K
Lung Capacity
56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Conserved Binding Sites
5.2K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
5.2K
Ligand Binding Sites
15.1K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.1K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Factors Affecting Protein-Drug Binding: Protein-Related Factors
575
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
575
